We explore bladder sensitivity profiles in females with chronic pelvic pain, using a non-invasive bladder sensitivity paradigm. We aim to determine how profiles differ between groups defined by symptoms; groups …
Letrozole and other aromatase inhibitors are increasingly recognized as first-line ovulation induction (OI) medications, offering an efficient and physiologic approach to ovarian stimulation that enhances outcomes in reproductive medicine. By …
Endometriosis is a heterogeneous pain condition with variable symptom expression. Abuse history has been associated with amplified pain, gastrointestinal symptoms, and central sensitization in varying populations; however, whether these effects …
Endometriosis is one of the main reproductive issues that the modifiable risk factors is still the main research focus. It is still unclear how various adiposity affect the onset and …
The human microbiota is increasingly recognized as a key component of women's reproductive health. This narrative review examines the vaginal, endometrial, and gut microbiota and their roles in the pathogenesis …
To evaluate whether the use of intraoperative indocyanine green (ICG) fluorescence impacts anastomotic safety and surgical outcomes in patients undergoing bowel endometriosis resection.
Estrogens play an important role throughout a woman's life; therefore, disrupting their physiological production will alter hormonal balance with consequences for estrogen-related conditions, such as endometriosis and adenomyosis. The gut …
Congenital obstructive genital tract anomalies are rare but clinically significant causes of menstrual outflow obstruction, endometriosis, and subfertility. Surgical correction aims to restore reproductive potential, yet evidence to guide counselling …
Menopause remains a largely neglected aspect of women's health in many low- and middle-income countries (LMICs), particularly across Asia, Africa, and the Middle East. Despite the profound physical, cognitive, and …
This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep …